Compare Carvana Co (CVNA) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Enveric Biosciences Inc — how do they compare? Carvana Co trades at $63.6 (market cap $69.07B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Carvana Co is far larger — about 10324.4× Enveric Biosciences Inc's market cap, and Carvana Co is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Enveric Biosciences Inc for 14 Days on average.
| CVNA | ENVB | |
|---|---|---|
Market Cap | $69.07B | $6.69M |
Volume | 6,556,641 | 41,141 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $10.80 |
52-Week Low | $56.27 | $1.27 |
Typical Hold Time | 28 Days | 14 Days |
Enterprise Value | $71.55B | -$1.60M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $62.76, down 1.72% on the day, amid a bearish technical signal despite strong fundamental performance. The company reported robust revenue growth, with 2025 revenue reaching $20.32B and net income of $1.41B, and has consistently beaten EPS estimates in recent quarters. Analyst consensus is mixed with a $84.07 price target, while technical indicators show resistance near $64 and support at $61.
Outlook remains cautiously optimistic given operational strength and growth trajectory, but high debt levels and competitive pressures pose risks. The stock offers upside if execution continues, yet volatility and macroeconomic factors warrant careful monitoring for investors.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
